retatrutide fda approval status november 2025 Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 clinical trials, is being sold openly across the internet and prescribed by licensed physicians online and GLP-1 Pipeline Update: August 2025

through the combination of sulfydryl and free radicals in vivo, the free radicals can be directly reduced and converted into easily metabolized acid substances, so that the excretion of the free radicals is accelerated, and the damage of the free radicals to important organs can be resisted

Metab Syndr Relat Disord

Furthermore, biomarkers of severe oxidative stress, such as 15-F2t-isoprostane, were significantly reduced in the supplemented group, proving that the extract was actively protecting the vascular walls from free radical damage

Why this matters clinically: sermorelin is the closest pharmacological approximation of normal GH physiology in this category